Laurion Capital Management LP Blueprint Medicines Corp Transaction History

Laurion Capital Management LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 13, 2019	SELL	$73.54 - $97.8 $19.3 Million - $25.6 Million	-261,904 Closed	0 $0
Q1 2019 May 08, 2019	BUY	$48.7 - $86.6 $12.8 Million - $22.7 Million	261,904 New	261,904 $21 Million
Q2 2018 Aug 13, 2018	SELL	$60.96 - $101.18 $390,144 - $647,552	-6,400 Closed	0 $0
Q1 2018 May 14, 2018	SELL	$73.28 - $102.95 $4.88 Million - $6.85 Million	-66,562 Reduced 91.23%	6,400 $587,000
Q4 2017 Feb 13, 2018	BUY	$62.91 - $88.32 $3.76 Million - $5.27 Million	59,690 Added 449.74%	72,962 $5.5 Million
Q3 2017 Nov 13, 2017	BUY	$42.37 - $69.67 $562,334 - $924,660	13,272	13,272 $925,000

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Laurion Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Laurion Capital Management LP with notifications on news.